Lv2
196 积分 2024-09-20 加入
Beyond Inhibition: Recent Advances of Heterobifunctional Molecules Targeting CDK9
1天前
待确认
Targeting CDK4 and CDK6 in cancer
1天前
已完结
EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation
1天前
已完结
Whole–genome characterization of chemoresistant ovarian cancer
1天前
已完结
Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer
7天前
已完结
Discovery of the First Potent PI3K/mTOR Dual-Targeting PROTAC Degrader for Efficient Modulation of the PI3K/AKT/mTOR Pathway
26天前
已完结
Aprocitentan, a dual endothelin-1 (ET-1) antagonist for treating resistant hypertension: Mechanism of action and therapeutic potential
1个月前
已完结
PROactively TACkling CDK4/6 therapy resistance
2个月前
已完结
Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer
2个月前
已完结
The Novel CDK9/CDK4/6/PI3K Triple Inhibitor LCI139 for the Treatment of MYC-Driven Mantle Cell Lymphoma
2个月前
已关闭
皖公网安备34019202002308
